A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease

Ivana Prokić 1*, Lies Lahousse 1,2, Maaike de Vries 3,4, Jun Liu 1,5, Marita Kalaaja 6, Judith M. Vonk 3,4, Diana A. van der Plaat 3,4,7, Cleo C. van Diemen 8, Ashley van der Spek 1, Alexandra Zhernakova 8, Jingyuan Fu 8,9, Mohsen Ghanbari 1,10, Mika Ala-Korpela 6,11, Johannes Kettunen 6,12, Aki S. Havulinna 12,13, Markus Perola 12,13, Veikko Salomaa 12, Lars Lind 14, Johan Årnlöv 15,16, Bruno H. C. Stricker 1, Guy G. Brusselle 1,17,18, H. Marike Boezen 3,4, Cornelia M. van Duijn 1,5† and Najaf Amin 1,5†

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a common lung disorder characterized by persistent and progressive airflow limitation as well as systemic changes. Metabolic changes in blood may help detect COPD in an earlier stage and predict prognosis.

Methods: We conducted a comprehensive study of circulating metabolites, measured by proton Nuclear Magnetic Resonance Spectroscopy, in relation with COPD and lung function. The discovery sample consisted of 5557 individuals from two large population-based studies in the Netherlands, the Rotterdam Study and the Erasmus Rucphen Family study. Significant findings were replicated in 12,205 individuals from the Lifelines-DEEP study, FINRISK and the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) studies. For replicated metabolites further investigation of causality was performed, utilizing genetics in the Mendelian randomization approach.

Results: There were 602 cases of COPD and 4955 controls used in the discovery meta-analysis. Our logistic regression results showed that higher levels of plasma Glycoprotein acetyl (GlycA) are significantly associated with COPD (OR = 1.16, P = 5.6 × 10⁻⁴ in the discovery and OR = 1.30, P = 1.8 × 10⁻⁶ in the replication sample). A bi-directional two-sample Mendelian randomization analysis suggested that circulating blood GlycA is not causally related to COPD, but that COPD causally increases GlycA levels. Using the prospective data of the same sample of Rotterdam Study in Cox-regression, we show that the circulating GlycA level is a predictive biomarker of COPD incidence (HR = 1.99, 95%CI 1.52–2.60, comparing those in the highest and lowest quartile of GlycA) but is not significantly associated with mortality in COPD patients (HR = 1.07, 95%CI 0.94–1.20).

Conclusions: Our study shows that circulating blood GlycA is a biomarker of early COPD pathology.

Keywords: COPD, Metabolomics, Mendelian randomization, Glycoprotein acetyl, Biomarkers

* Correspondence: inedeljkovic@erasmusmc.nl
† Cornelia M. van Duijn and Najaf Amin contributed equally to this work.

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease and currently the third leading cause of death worldwide [1, 2]. COPD is characterised by chronic airway inflammation, airway remodelling and airflow limitation [3]. A reduced ratio of the Forced Expiratory Volume in 1 s (FEV₁) to Forced Vital Capacity (FVC) is a measure of obstruction and is used to diagnose COPD even before the onset of clinical symptoms [3, 4]. Smoking is the most important risk factor for COPD and related to impaired lung function [2]. COPD is a complex heterogeneous disease in which systemic features beyond airflow obstruction, including systemic inflammation, oxidative stress, muscle dysfunction, cachexia and vascular pathology occur [5, 6]. Understanding these systemic effects may give new insights into the pathogenesis and progression of COPD but may alternatively yield important clues for preventive research.

Recent developments in metabolomics have made it possible to investigate the associations between circulating metabolites and COPD. Glycoprotein acetyl (GlycA) was found to be predictive for several chronic diseases, among which COPD [7]. In a previous metabolomics study using proton Nuclear Magnetic Resonance (¹H-NMR), lower levels of lipoproteins, N,N-dimethylglycine and higher levels of glutamine, phenylalanine, 3-methylhistidine and ketone bodies were found in the circulation of ex-smoking COPD patients compared with ex-smoking controls [8]. In severe COPD patients, branched chain amino acids (BCAAs) were found to be lower, compared with controls [8]. Interestingly, BCAAs, 3-methylhistidine, ketone bodies, and triglycerides were negatively correlated with cachexia and positively correlated with systemic inflammation [8], but these findings have not been replicated. Another question that remains to be answered is whether the metabolic changes are a cause or a consequence of COPD. If the latter is true, the metabolites may be relevant for the disease progression and prognosis.

To answer these questions, we performed a comprehensive integrative metabolic analysis to identify plasma metabolic measures associated with COPD and lung function levels, defined as FEV₁/FVC, using the NMR approach in a set of large epidemiological studies, in depth characterized for genetic and environmental risk factors. The discovery phase of the study was conducted in two population-based studies in the Netherlands, the Rotterdam Study (RS) [9] and the Erasmus Rucphen Family study (ERF) [10, 11]. A replication meta-analysis was conducted in the Lifelines-DEEP study (LLDEEP) [12], two cohorts of the FINRISK study [13, 14] and the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study [15, 16].

Methods
Study population

Studies included in the discovery sample

The RS is a population-based study of 14,926 people older than 45 years, from the Ommoord area of Rotterdam, incorporating three independent cohorts: RS-I (established in 1989), RS-II (2000) and RS-III (2006), with multiple subsequent visits [9]. Participants filled in questionnaires, underwent physical examination and provided fasting blood samples at each visit. For this analysis, three independent samples from different RS cohorts were enrolled: Sample 1) visit 4 of RS-I (RS-I-4); sample 2) a combined sample, which we collectively call RS-E5 in this manuscript, comprising of visit 5 of RS-I (RS-I-5), visit 3 of RS-II (RS-II-3), and visit 2 of RS-III (RS-III-2); and sample 3) another independent set from RS-III-2.

ERF is a population-based study from the south-west of the Netherlands. It is a genetically isolated population comprising 3465 living descendants of 22 couples from the nineteenth century and their spouses [10]. The baseline data collection was performed in 2002–2005 when participants underwent physical examinations, provided blood samples and completed questionnaires. A follow-up of the participants was performed in 2015–2018, reviewing the medical records at the general practitioner’s office.

Studies included in the replication sample

LLDEEP is a sub-cohort of the large general population-based cohort study Lifelines, which was initiated to study genes, exposures and their interactions in the aetiology of complex multifactorial diseases and healthy ageing [17, 18]. LLDEEP consists of 1500 participants who registered at the Lifelines research site in Groningen between April and August 2013. These subjects gave additional biological materials, including blood samples for metabolite and inflammation profiling, and extensive phenotype information [12]. Metabolic and lung function data were available for 717 LLDEEP individuals and these subjects are included in the current study.

The FINRISK cohorts comprise cross-sectional population surveys that are carried out every 5 years since 1972, to assess the risk factors of chronic diseases (e.g. cardio-vascular disease, diabetes, obesity, cancer) and health behaviour in the working age population (25–74 years of age), in 3–5 large study areas of Finland. The FINRISK surveys are conducted by the National Institute for Health and Welfare, THL (previously National Public Health Institute, KTL). Extensive information from each participant was collected at baseline via questionnaire and health examination with blood collection. The cohorts were followed up by linking them to national health registers. The cohorts FINRISK 1997 (total of
6898 participants) and an extension of FINRISK 2007, known as DILGOM and 10 years for FINRISK97.

In the PIVUS study the COPD information was extracted based on diagnoses and reimbursement information from the National health register, which include the Drug Reimbursement Register, the Care Register for Health Care, the Register for Prescribed Drug Purchases, the Causes-of-Death Register, and the Cancer Register. The maximum retrospective time period available for obtaining prevalent disease events was 20 years for DILGOM and 10 years for FINRISK97.

In the PIVUS study FEV1 and FVC were assessed with spirometry using a Vitalograph Alpha spirometer (Vitalograph Ltd. Buckingham, United Kingdom) according to the American Thoracic Society recommendations [20, 21]. The best value of three acceptable recordings was used. FEV1 and FVC expressed as percent of predicted values, were adjusted for age, sex and height according to Hedenström’s formula [22, 23]. The PIVUS study was included only in the FEV1/FVC analysis, as this study does not have confirmed diagnosis of COPD by lung specialist.

Assessment of blood metabolites
Metabolic profiling in RS, ERF and LLDEEP was done as part of the 4th Rainbow Project of the BioBanking for Medical Research Infrastructure of the Netherlands (BBMRI-NL) (https://www.bbmri.nl/omics-metabolomics/). For all studies used in the discovery and replication samples, to quantify the metabolite biomarkers random selection of fasting EDTA plasma samples were used for quantitative high-throughput 1H-NMR metabolomics platform performed by the same company using the same standardized quality control protocol (Nightingale Ltd., Helsinki, Finland). All samples were stored at −80 °C which ensures the biological stability. Details of the protocol and advantages of the NMR-based metabolomics analyses using plasma were described elsewhere [24, 25]. The protocol describes steps for quality control and sample preparation, data storage and spectral analyses. If metabolite values were flagged to be unreliable by the quality control protocol, they were treated as missing. If distributions of the metabolites deviated from normal, every cohort applied normalization steps as suggested by Nightingale. Those included natural logarithm transformation and scaling to standard deviation units. Using this method, we were able to quantify a wide range of blood metabolite biomarkers such as lipoprotein fractions, amino-acids, cholesterol levels, glycerides, phospholipids, fatty acids, ketone bodies and metabolites related to inflammation and glycolysis. In total, 161 metabolites, overlapping between RS and ERF, were used in the discovery analysis.

Statistical analyses
Association of COPD and FEV1/FVC with metabolites
Per cohort, we used transformed metabolite levels as independent variable and COPD status or FEV1/FVC as
dependent variables in logistic and linear regression models, respectively. The models were adjusted for age, sex, body mass index (BMI, kg/m²), lipid lowering medication (LLM) use and smoking status (current, ex- or never smokers). For the discovery sample, the results from ERF, RS-I-4, RS-E5 and RS-III-2 were meta-analysed using fixed effect models in “METAL” software [26]. As the metabolites are known to be highly correlated, we applied the method by Li and Ji [27] to assess the number of independent metabolites. Using this method, we calculated that for the 161 metabolites, the number of independent tests was 45, which resulted in the Bonferroni significance threshold of \( P = 0.001 \) (0.05/45). Significant metabolites were further tested for replication in the meta-analysis of LLDEEP, FINRISK1997 and DILGOM studies for the COPD analysis and of LLDEEP and PIVUS studies for the FEV₁/FVC analysis. Again, the same regression models were used for the fixed effect meta-analysis in “METAL” software.

For significant metabolites, we calculated the odds ratios per quartile of the metabolite distribution in the discovery sample. To investigate the effects of smoking on this association, we used two logistic regression models, one adjusted for age, sex, BMI and LLM use, and a second model additionally adjusted for smoking status (current, ex- and never smokers). Results from each cohort were combined using inverse-variance weighted fixed effects meta-analysis in “rmeta” package in R.

**Exploring causality of the association between COPD and metabolites**

We have used a bi-directional approach in which we examined whether: 1) the genetic determinants of the significant metabolites are associated with COPD and lung function, which would lead to the conclusion that the metabolites are most likely driving the disease; 2) the genetic determinants of COPD are associated with significant metabolites when the metabolites would most likely be altered as an integral part of the disease pathophysiology and may be biomarkers. The R package “TwoSampleMR” was used for the two sample Mendelian Randomization (MR) tests [28, 29]. We used the genetic information from previously published genome-wide association studies (GWAS) on metabolites (Model 1) [25] and COPD (Model 2) [30]. In brief, the genetic score was based on the top single nucleotide polymorphisms (SNPs, \( P \)-value < 5 \( \times \) 10⁻⁸) with linkage disequilibrium (LD) \( R² < 0.05 \) within 500 kb clumping distance. Harmonization was checked, including the strand issues and palindromic SNPs. It resulted in eight independent SNPs for COPD (\( R² = 1.7% \)), and nine SNPs for GlycA (\( R² = 2.3% \)). Inverse variance weighted MR, Maximum likelihood MR, MR Egger analysis and median-based estimator were performed to check the significant results.

**Association with morbidity and mortality**

We wanted to investigate whether an identified metabolite in the circulation is a biomarker of early pathology thus can be used as a predictive or diagnostic biomarker or rather prognostic biomarker for mortality in COPD patients. To this end, we performed an analysis in the Rotterdam Study in which we associated identified metabolite to the future risk of COPD. We determined the relative risk by quartile of the metabolite concentration in the circulation, using the lowest quartile as a reference. Only incident patients are included in this analysis (whole RS sample, in total 541 case and 4407 controls); prevalent COPD patients are excluded. To investigate whether metabolites have utility in predicting COPD, we constructed classical receiver operating curves (ROC) and compared areas under the curve (AUC) [31]. To further investigate whether the identified metabolites may act as biomarker of the disease prognosis, we performed a survival analysis in SPSS, similar to the previous study by Fischer and colleagues for all-cause mortality, ignoring any underlying morbidity [32]. To check whether the metabolites associated with mortality in COPD patients, we performed the Cox proportional hazards model in three RS cohorts. Analyses were adjusted for age at sampling, sex and smoking. We further performed a similar analysis using four quartiles of metabolite, testing in COPD cases and controls.

**Results**

**Descriptive characteristics of the samples**

Descriptive characteristics of all cohorts used in the analysis are presented in Table 1. Comparing the discovery cohorts, ERF participants were younger (mean age 49.0 ± 13.3) and had a higher percentage of current smokers compared to the participants of the three RS cohorts (RS-I-4 mean age 74.8 ± 6.5; RS-E5 mean age 68.4 ± 5.7; RS-III-2 mean age 62.8 ± 5.8). The RS cohorts had a higher percentage of users of the LLM, compared to ERF (Table 1).

The mean FEV₁/FVC and BMI were comparable across the studies. Descriptive characteristics for COPD cases and subjects without COPD separately in the discovery cohorts are provided in eTable 1 in the Supplementary. In general, COPD subjects were older and more often smokers compared to subjects without COPD. Since FINRISK97 and DILGOM studies are based on the data from National health registers, and thus do not have minimum age entry criteria, the percentage of COPD cases is lower compared with discovery sample, containing elderly population.

**Association of COPD and FEV₁/FVC with metabolites**

In the discovery sample, six plasma metabolites were associated with COPD at a significance level of 5% (Table 2, Fig. 1).
Table 1 Discovery population characteristics per cohort

| Study | Discovery cohorts | Replication cohorts |
|-------|------------------|---------------------|
|       | ERF | RS-I-4 | RS-ES | RS-III-2 | LLDEEP | FINRISK97 | DILGOM | PIVUS |
| N | 609 | 2777 | 686 | 1485 | 717 | 6898 | 4600 | 854 |
| Age, mean (sd) | 49.0 (13.3) | 74.8 (6.5) | 68.4 (5.7) | 62.8 (5.8) | 46.0 (14.3) | 48.0 (13.1) | 53.4 (2458) | 48.2 (412) |
| Women, % (n) | 30.0 (183) | 56.1 (1559) | 57.0 (391) | 50.2 (746) | NA | 22.9 (1577) | 26.3 (1210) | 41.5 (354) |
| Ex-smokers, % (n) | 30.0 (183) | 56.1 (1559) | 57.0 (391) | 50.2 (746) | NA | 22.9 (1577) | 26.3 (1210) | 41.5 (354) |
| Never smokers, % (n) | 26.6 (162) | 31.3 (869) | 33.5 (230) | 36.1 (536) | 79.4 (570) | 53.2 (3673) | 56.1 (2580) | 48.2 (412) |
| BMI, mean (sd), % of all | 27.2 (4.85) | 27.4 (4.1) | 27.8 (4.3) | 27.4 (4.5) | 25.4 (4.1) | 26.6 (4.5) | 27.2 (4.8) | 27.1 (4.26) |
| COPD cases, % (n) | 10.0 (61) | 12.1 (336) | 10.3 (71) | 9.0 (134) | 13.8 (99) | 0.6 (43) | 0.8 (35) | NA |
| FEV1/FVC, mean (sd), % of all | 4.7 (2) | 5.6 (2.2) | 5.6 (2.2) | 5.6 (2.2) | 6.0 (2.2) | 6.0 (2.2) | 6.0 (2.2) | 6.0 (2.2) |
| Pack-years of smoking, mean (sd), % of all | 24.9 (20.4) | 24.2 (23.4) | 22.0 (20.8) | 19.5 (20.3) | NA | 22.9 (1577) | 26.3 (1210) | 41.5 (354) |
| LLM users, % (n) | 12.3 (75) | 22.4 (621) | 32.5 (223) | 22.2 (329) | 3.9 (28) | 3.4 (237) | 15.7 (721) | 16.5 (141) |

At nominal significance, higher levels of GlycA (odds ratio \(OR = 1.16; \ P = 5.6 \times 10^{-4}\), 3-hydroxybutyrate (OR = 1.13; \ P = 0.003), free cholesterol in medium high-density lipoprotein (HDL, OR = 1.10; \ P = 0.045) and acetoacetate (OR = 1.09; \ P = 0.047) were associated with a higher prevalence of COPD. Other metabolites that reached nominal significance in the discovery included albumin which was positively associated with a lower FEV1/FVC ratio (Table 3, Fig. 1).

Findings for the FEV1/FVC ratio were not consistent over the discovery and replication studies. Adjusting for multiple testing, we found in the discovery cohorts that lower levels of valine (\(\beta = 0.005, \ P = 2.5 \times 10^{-4}\)) and higher levels of GlycA (\(\beta = -0.005, \ P = 4.5 \times 10^{-4}\)) were associated with a lower FEV1/FVC ratio (Table 3, Fig. 1).

Table 2 Metabolites associated with COPD in the discovery and replication studies

| Metabolite | Discovery meta-analysis | Replication meta-analysis |
|------------|-------------------------|---------------------------|
| GlycA | 0.152 | 0.044 | 1.16 | \(5.6 \times 10^{-4}\) | ++ | N | 0.266 | 0.053 | 1.30 | \(1.8 \times 10^{-6}\) | +++ | N |
| 3-hydroxybutyrate | 0.122 | 0.041 | 1.03 | \(5.6 \times 10^{-4}\) | ++ | N | 0.023 | 0.057 | 0.97 | 0.662 | -- | 12,173 |
| Histidine | -0.097 | 0.047 | 0.91 | 0.037 | -- | -- | N | 0.153 | 0.063 | 0.86 | 0.020 | --- | 12,200 |
| Free cholesterol in med. HDL | 0.099 | 0.049 | 1.00 | 0.045 | + | --- | N | 0.004 | 0.063 | 1.00 | 0.867 | -- | 12,208 |
| Acetoacetate | 0.084 | 0.032 | 1.05 | 0.047 | ++ | | N | 0.061 | 0.059 | 0.94 | 0.360 | --- | 12,201 |
| 18:2, linoleic acid | -0.095 | 0.048 | 0.91 | 0.049 | ++ | | N | 0.036 | 0.057 | 0.96 | 0.238 | ++ | 12,167 |

Model adjusted for age, sex, BMI, LLM use and smoking status; GlycA Glycoprotein acetyls, HDL high density lipoprotein, \(\beta\) effect size, SE standard error, OR odds ratio; Direction - direction of the effect in individual studies; N - meta-analysis sample size; ++ Direction of the effect in the discovery studies in order: ERF, RS-III-2, RS-ES, RS-I-4; \(\beta\) direction of the effect in the replication studies in order: LLDEEP, FINRISK97, DILGOM; In bold: significant results (\(P < 0.001\))
COPD and FEV₁/FVC in the discovery sample are provided in the supplementary material (eTable 4 and eTable 5, respectively).

Exploring causality of COPD and circulating GlycA

Next, we performed a Mendelian Randomisation experiment investigating the hypothesis that: 1) GlycA is increasing the risk of COPD and therefore the genetic determinants of GlycA (used as instrumental variables) are also associated with COPD and 2) the opposite scenario is true in which (pre)clinical COPD pathology increases GlycA levels. The results of both models are presented in Table 4.

The genetic risk score (GRS) for Model 1 included nine independent SNPs (R² = 2.3%) and yielded no significant evidence for association (P = 0.97 for inverse variance weighted method). In Model 2, we found that genes associated with a higher risk of COPD are also associated with higher levels of GlycA, through the COPD (Table 4, P = 0.00068 for inverse variance weighted method), suggesting that COPD pathology increased GlycA levels. The results of weighted median and weighted mode were significant as well (P-value < 0.05).

Is circulating GlycA predictive biomarker for COPD?

Compared to the lowest quartile, those subjects in the highest quartile of GlycA had a 1.99-fold (95% Confidence interval: 1.52–2.60) higher risk of developing COPD, after adjustment for age, sex, BMI and LLM use (eTable 2). Smoking accounted for a part of the observed association between plasma GlycA and COPD attenuating the OR for those in the highest quartile of GlycA to 1.74, while the association remained significant (95% Confidence interval: 1.32–2.28). To test whether circulating GlycA adds to the predictive value, we compared the AUC curves for the models including: 1) age and sex (AUC = 0.601); 2) age, sex and smoking (AUC = 0.670) and 3) age, sex, smoking and circulating GlycA levels in blood (AUC = 0.675). The AUC comparing model 2 and 1 shows that smoking is associated with an increase in AUC by 0.069. Adding circulating GlycA increased the AUC further by only 0.005 (eFigure 1).

![Fig. 1 Top metabolites associated with COPD and/or FEV₁/FVC. Colors represent standardized effect estimates of the metabolite association with corresponding trait (COPD, FEV₁/FVC). Red color means that the trait is associated with a higher metabolite concentration, while blue represents a lower metabolite concentration. For replicated metabolites, replication P-value is shown with stars: *P < 0.05 and ***P < 0.001. HDL – high-density lipoprotein](image)

### Table 3 Top metabolites associated with FEV₁/FVC - Results of the discovery and replication studies

| Metabolite            | Discovery meta-analysis | Replication meta-analysis |
|-----------------------|-------------------------|---------------------------|
|                       | β  | SE  | P-value | Direction | N   | β  | SE  | P-value | Direction | N   |
| Valine                | 0.005 | 0.001 | 2.5 × 10⁻⁴ | +++        | 3324 | -0.0015 | 0.0023 | 0.5314 | -- | 1460 |
| GlycA                 | -0.005 | 0.001 | 4.5 × 10⁻⁴ | ---        | 3324 | -0.0010 | 0.0022 | 0.6438 | --- | 1463 |
| Albumin               | 0.004 | 0.001 | 0.0047 | +++        | 3324 | 0.0045 | 0.0021 | 0.0353 | ++ | 1463 |
| Glutamine             | -0.003 | 0.001 | 0.0097 | ---        | 3324 | 0.0029 | 0.0023 | 0.1923 | ++ | 1393 |
| Triglycerides in very large HDL | -0.003 | 0.001 | 0.0160 | ---        | 3324 | 0.0031 | 0.0022 | 0.1491 | ++ | 1469 |
| Phenylalanine         | -0.003 | 0.001 | 0.0334 | ---        | 3324 | -0.0012 | 0.0023 | 0.5899 | ++ | 1450 |

Model adjusted for age, sex, BMI, LLM use and smoking status; HDL high density lipoprotein; β effect size, SE standard error; Direction - direction of the effect in individual studies; N - meta-analysis sample size; * Direction of the effect in the discovery studies in order: RS-III-2, RS-ES, RS-I-4; ** Direction of the effect in the replication studies in order: LLDEEP, PIVUS; In bold: significant results (P < 0.001).
Is circulating GlycA a prognostic biomarker for mortality in COPD?
A previous study has shown that GlycA is a predictor of all-cause mortality in the general population [32]. We confirm this in our current study, after adjustment for age, sex and smoking (hazard ratio (HR) = 1.16, \( P = 4.39 \times 10^{-9} \)) (eTable 3). The mean follow-up time in years was 6.94, ranging from 0.04 to 15.96. We first performed the analysis with continuous GlycA and then compared mortality across the quartiles of GlycA. We found that those in the highest quartile have 1.4-fold (95% Confidence interval: 1.22–1.61, \( P = 1.64 \times 10^{-6} \)) higher risk of mortality during follow-up compared to those in the lowest quartile (eTable 3). However, when stratifying these analyses by COPD status, we observed that this association is driven by controls (eTable 3; eFigure 2). In COPD patients, circulating GlycA levels are not significantly associated with mortality when studying GlycA as a continuous variable (HR = 1.06, \( P = 0.32 \)) nor for those in the highest quartile (HR = 1.07, \( P = 0.70 \) in COPD cases). In those without COPD, the association of continuous GlycA to mortality is stronger and significant (HR = 1.18, \( P = 1.43 \times 10^{-9} \)).

Discussion
In our metabolome-wide discovery analysis, we identified 11 plasma metabolites associated with COPD or lung function levels (FEV1/FVC) at marginal significance. Of these 11 metabolites, only higher levels of GlycA were significantly associated with COPD when adjusting for multiple testing and this is the only metabolite we could replicate in the independent cohorts. Our MR analysis suggested a causal relation between COPD and higher GlycA levels in the circulation by showing that the genetic predisposition to COPD associates with GlycA. The GlycA level seemed to be an early biomarker of COPD since it was associated with the incidence of COPD, even after adjustment for smoking. Although GlycA was found to be a predictor of mortality in the general population [33], the metabolite did not predict mortality in COPD patients. GlycA is the most convincing and interesting finding of our study. This metabolite was recently associated with the incidence of a variety of disorders, including COPD based on record linkage [7]. Using two population-based cohorts, we identified new associations with GlycA including alcoholic liver disease, chronic renal failure, glomerular diseases and inflammatory polyarthropathies. The GlycA associations were for a large part independent of that of high-sensitivity C-reactive protein (hsCRP), but GlycA and hsCRP also share contributions to mortality risk, suggesting chronic inflammation as the common pathway. GlycA is shown to be a biomarker for chronic inflammation, neutrophil activity and risk of future severe infection, even superior compared with CRP [34, 35].

The present study extends previous research by widening the number of NMR metabolites studied and we found that GlycA is the only metabolite significantly associated with COPD after adjusting for multiple testing. Our analyses were adjusted for smoking and the association between GlycA and COPD is thus not explained by smoking. We used data integration approach (MR) to test the hypothesis that GlycA increases the risk of COPD causally or rather is a bystander biomarker that is part of the disease pathogenesis (marker of the disease). Our findings suggest that the latter is more likely, as the genes associated with COPD also associate with GlycA levels. In contrast, no support was found for the hypothesis that GlycA is a causal determinant of COPD: the genes that are known to be associated with GlycA levels are not associated with the risk of COPD. The findings of the MR are in line with the finding that GlycA was not consistently associated with the

### Table 4 Results of the bi-directional MR approach on GlycA and COPD

| Model | Exposure | Outcome | \( R^2 \) | nSNP | Method                  | \( \beta \)   | SE     | \( P \)-value |
|-------|----------|---------|-----------|------|------------------------|--------------|--------|--------------|
| 1     | GlycA    | COPD    | 2.30      | 9    | Inverse variance weighted | 0.001        | 0.027  | 0.97         |
|       |          |         |           |      | Weighted median         | -0.009       | 0.029  | 0.76         |
|       |          |         |           |      | Weighted mode           | -0.028       | 0.039  | 0.49         |
|       |          |         |           |      | Simple mode             | -0.013       | 0.046  | 0.79         |
|       |          |         |           |      | MR Egger                | -0.140       | 0.147  | 0.37         |
| 2     | COPD     | GlycA   | 1.72      | 8    | Inverse variance weighted | 0.306        | 0.090  | 0.00068      |
|       |          |         |           |      | Weighted median         | 0.348        | 0.115  | 0.0024       |
|       |          |         |           |      | Weighted mode           | 0.378        | 0.150  | 0.04         |
|       |          |         |           |      | Simple mode             | 0.359        | 0.157  | 0.06         |
|       |          |         |           |      | MR Egger                | 0.412        | 0.624  | 0.53         |

\( R^2 \) - the explained variance in the exposure by applied genetic risk score; nSNP - number of SNPs used to construct the genetic risk score; \( \beta \) - the weighted effect of the genetic risk score of exposure on outcome; SE - standard error; Significance threshold = \( P \)-value < 0.05. The Egger regression is a test to check the assumption of the instrument strength being independent of the direct effect to the outcome and should be \( P > 0.05 \).
FEV₁/FVC ratio across the discovery and replication cohorts, which suggests that GlycA is more likely increased as an early consequence of the developed disease. This is in line with other studies on different diseases involving systemic inflammation. However, as many other factors, aside from genetics, play a role in this complex disease and blood metabolic patterns, our MR results need further corroboration using experimental animal models to support the causality.

Although it is known to be a marker of acute inflammation, it has also been shown that it is predictive of long-term risk of severe infection, and high levels correlated with an increased risk of hospitalization and death from septicaemia and pneumonia [34]. This is particularly important for exacerbations of COPD and the prognosis. In the present paper we do not find evidence that GlycA is associated with COPD mortality. Such relationship was seen for cardiovascular disease. GlycA not only increased the risk of incident cardiovascular disease [7, 36] but was also associated with a 5-fold increased 12-year risk of mortality in those with the highest GlycA levels [7]. This suggests that our analysis would benefit from increasing the sample size even more.

GlycA, is a composite NMR-based signal related to changes in multiple circulating glycoproteins, mainly orosomucoids [37], which are a positive acute phase proteins, and their concentration increases in response to systemic inflammation. However, as many other factors, aside from genetics, play a role in this complex disease and blood metabolic patterns, our MR results need further corroboration using experimental animal models to support the causality.

Another strength is the use of the NMR platform, which is valued for being non-invasive, non-destructive, fast and for providing highly reproducible results [45]. A limitation of this study is our COPD definition, mainly based on pre-bronchodilator lung function measurements or review of medical records and national registries, which may have introduced some selection bias. Nevertheless, we do identify and replicate significant results which should be further corroborated in studies with post-bronchodilator measures. Our MR approach allowed us to gain more insight into the direction of the effects, suggesting that GlycA is an independent biomarker of COPD. Yet we have to acknowledge that MR is limited to the knowledge of the genetic determinants of both COPD and GlycA. In addition, we acknowledge possible limitations of MR due to pleiotropy, the lack of trans-ethnic studies and remaining bias due to canalization.

Conclusions
Altogether, combining the epidemiological data with our MR analyses suggests that GlycA is a biomarker of COPD inflammatory pathways, present in higher concentrations even before the COPD is clinically present. Further studies should investigate the possibility for GlycA to serve as a prediction tool for COPD morbidity and severity. Further functional studies investigating the role of GlycA in COPD will provide more insight into the pathogenesis, prognosis and treatment response of patients with COPD. Our study highlights the power of cross-omics and epidemiological data integration.
to the members of the International COPD Genetics Consortium and Michael Cho for sharing the data of their published GWAS of COPD.

Authors’ contributions
IP, MdV, JL, AvdS and MK were involved in the analysis of the data; IP, LLa, JMV, DvdP, JK, ASH, MG, MP, VS, LLI, JA, BHCS, AZ, JF, MAK and GGB were involved in data collection/preparation; IP, LLa, MdV, JMV, DvdP, CcVdD, HMb, CHVdM, MAK and NA contributed to the conception and design of this work and were involved in the interpretation of the results; All authors were involved in writing and critically revising the manuscript, approved the final manuscript and agreed to be accountable for it.

Funding
This work was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO, grant nr 41.13.007 of Lung Foundation Netherlands (Longfonds). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam.

The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-019497) and also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013/ grant agreement HEALTH-F4–2007–201413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no.QLG2-CT-2002-01254). The ERF study was further supported by ENGAGE consortium and CMB. High-throughput analysis of the ERF data was supported by joint grant from Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043).

LLDEEP was funded by the Netherlands Heart Foundation (IN-CONTROL CVON grant 2012–03 to A.Z. and J.F.); by the Netherlands Organization for Scientific Research (NWO) (NWO-VIDI 864.13.013 to JF, NWO-VIDI 016.178.056 to AZ, and by the European Research Council (ERC) (ERC Starting Grant 715772) to AZ. AZ also holds a Rosalind Franklin Fellowship from the University of Groningen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. FINRISK surveys are mainly funded by the budgetary funds of the National Institute for Health and Welfare. Additional funding has been obtained from the Finnish Academy (#139635 and 118065) and from domestic foundations, such as the Finnish Foundation for Cardiovascular Research (to VS). JK was supported through funds from the Academy of Finland (grant numbers 297338 and 307247) and Novo Nordisk Fondens (grant number NNF17OC0026062). MAK and JK are funded by a research grant from the Sigrid Juselius Foundation, Finland. PWUS study was funded by Uppsala University Hospital.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available due to the stringent consent form requirements signed by the study participants, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Both RS and ERF were approved by the Medical Ethics committee of the Erasmus Medical Center and all participants gave informed consent for participation in the study and for evaluation of the available information from their physicians. LLDEEP was approved by the ethics committee of the University Medical Center Groningen and all participants signed an informed consent prior to enrolment.

The FINRISK 1997 study was approved by the Ethical Committee of the National Public Health Institute, while the DILGOM study was approved by the Coordinating Ethical Committee of the Hospital District of Helsinki and Uusimaa. All participants have signed an informed consent, allowing the use of their data and samples for studying environmental and genetic risk factors of chronic diseases. The Ethics Committee of the University of Uppsala approved the study and the participants gave informed consent (approval number 00–419).

Consent for publication
Not applicable.

Competing interests
All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. VS has participated in a conference trip sponsored by Novo Nordisk and received a modest honorarium from the same source for participating in an advisory board meeting. He also has ongoing research collaboration with Bayer Ltd.

Author details
1Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
2Department of Bioanalysis, Pharmaceutical Care Unit, Ghent University, Ghent, Belgium.
3Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
4Groningen Research Institute for Asthma and COPD (GRAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
5Nuffield Department of Population Health, University of Oxford, Oxford, UK.
6Computational Medicine department, Center for Life Course Health Research, Biocenter Oulu, University of Oulu, Oulu, Finland.
7National Heart and Lung Institute, Imperial College London, London, UK.
8Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
9Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
10Department of Genetics, School of Medicine, Marshall University, South Carolina, USA.
11NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
12Finnish Institute for Health and Welfare, Helsinki, Finland.
13Molecular Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
14Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
15Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden.
16School of Health and Social Sciences, Dalarna University, Falun, Sweden.
17Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
18Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Received: 12 April 2020 Accepted: 29 June 2020
Published online: 16 July 2020

References
1. World Health Organization - WHO. World Health Statistics 2008: World Health Organization; 2008.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–213.
3. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.
4. Wain LV, Shrine N, Artigas MS, et al. Supplementary: genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat Genet. 2017;49(3):416–25. https://doi.org/10.1038/ng.3787.
5. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4): 865–73. https://doi.org/10.1183/09031936.0011707.
6. Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122.
7. Kettunen J, Ritchie SC, Anufrieva O, et al. Biomarker glycoprotein acetyls is associated with the risk of a wide Spectrum of incident diseases and stratifies mortality risk in angiography patients. Circ Genomic Precis Med. 2018;11(1):e002234. https://doi.org/10.1161/CIRCGEN.118.002234.
8. Ulthi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J. 2012;40(2):345–55. https://doi.org/10.1183/09031936.00112411.

9. Ikram MA, Brusselle G, Ganbari M, et al. Objectives, design and main findings until 2020 from the Rotterdam study. Eur J Epidemiol. 2020. https://doi.org/10.1007/s10654-020-00640-5.

10. Pardo LM, MacKay I, Oostra B, van Duijn CM, Aulchenko YS. The effect of genetic drift in a young genetically isolated population. Ann Hum Genet. 2005;69(3):288–95. https://doi.org/10.1046/j.1529-8817.2005.00162.x.

11. Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen family study. J Med Genet. 2008;45(9):572–7. https://doi.org/10.1136/jmg.2008.058388.

12. Tichghekar EF, Zhenakova A, Dekens JM, et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open. 2015;5(8):e006772. https://doi.org/10.1136/bmjopen-2014-006772.

13. Borodulin K, Tontoni H, Jousilahti P, et al. Cohort Profile: The National FINR ISK Study. Int J Epidemiol. 2018;47(3):606–696. https://doi.org/10.1093/ije/dyx239.

14. Borodulin K, Vartiainen E, Peltonen M, et al. Forty-year trends in cardiovascular risk factors in Finland. Eur J Publ Health. 2013;25(3):539–46. https://doi.org/10.1093/eurpub/cku714.

15. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the prospective investigation of the vasculature in Uppsala seniors (PIVUS) study. Arterioscler Thromb Vasc Biol. 2005;25(11):2368–75. https://doi.org/10.1161/01.ATV.0000184769.22061.da.

16. Salihovic S, Ganna A, Fall T, et al. The metabolic fitter genterprint of p., p -DOE and HCB exposure in humans. Environ Int. 2016. https://doi.org/10.1016/j.envint.2015.12.015.

17. Scholten S, Smidt N, Swertz MA, et al. Cohort profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol. 2015;44(4):1172–80. https://doi.org/10.1093/ije/dyu229.

18. Stolk RP, Rosmalen JGM, Postma DS, et al. Universal risk factors for multifactorial diseases. Eur J Epidemiol. 2008;23(1):67–74. https://doi.org/10.1007/s10654-007-9204-4.

19. Kontrimen H, Llewellyn C, Silventoinen K, et al. Genetic predisposition to obesity, restrained eating and changes in body weight: a population-based prospective study. Int J Obes. 2018;42(4):858–65. https://doi.org/10.1038/ijo.2017.278.

20. Engström G, de Verdier MG, Dahlbäck M, Janson C, Lind L. BP variability and cardiovascular autonomic function in relation to forced expiratory volume: a population-based prospective study. Chest. 2009;136(1):177–83. https://doi.org/10.1378/chest.08-2529.

21. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3):1107–16. https://doi.org/10.1164/ajccrm.152.3.6636792.

22. Hedenström H, Malmberg P, Fridriksson HV. Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci. 1968;63(1):299–310. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC381032. Accessed 15 Nov 2018.

23. Hedenström H, Malmberg P, Agawal K. Reference values for lung function tests in females. Regression equations with smoking variables. Bull Eur Physiopathol Respir. 21(6):551–7. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074961. Accessed 15 Nov 2018.

24. Sortinen P, Kangas AJ, Wurtz P, Sutva T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8(1):193–206. https://doi.org/10.1161/CIRCGENETICS.114.000216.

25. Kettunen J, Demirkan AA, Wurtz P, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun. 2016;7:11122. https://doi.org/10.1038/ncomms11122.

26. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190–1. https://doi.org/10.1093/bioinformatics/btp340.

27. Li J, Ji L. Adjusting multiple testing in multilocus analysis using the eigenvalues of a correlaton matrix. Heredity (Edinb). 2005;95(3):1–7.